Found 706 clinical trials
Observational Study of Outcomes after EchoMark and EchoSure-based Free Flap Monitoring
The purpose of this study is to evaluate the performance of the EchoMark and EchoSure (both FDA approved devices) as an ultrasound-based method of monitoring the viability of free flaps and patency of at-risk vessels. The implant and ultrasound will be used per IFU. The primary purpose of the study …
Implementing the screen and treat strategy for prevention of cryptococcal disease in Botswana: An efficacy and costing study (study protocol V1.5 16th March 2017)
Adult HIV prevalence in Botswana is estimated at 25%. In 2013, despite widespread availability of antiretroviral therapy (ART), an estimated one-quarter of patients did not initiate ART until their CD4 count was below 147 cells/microL. The early mortality rate in these individuals is high, and cryptococcal meningitis is a leading …
A Phase 1 Open-Label Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
UPCC 10519 / I5B-MC-Y001: An Open-Label Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
The purpose of this program is to allow patients who, in consultation with their treating physician, feel it is in their best interest to continue to receive olaratumab. Only patients with soft tissue sarcoma who are already being treated with olaratumab may enter this program.
UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer
The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.
UPCC 31218: A prospective multicentre randomised controlled study evaluating SIR-Spheres Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM) chemotherapy versus CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic CholangioCArcinoma (SIRCCA)
The main purpose of this research study is to find out whether Selective Internal Radiation Therapy (SIRT) preceding a standard chemotherapy treatment can improve survival in patients with cholangiocarcinoma in the liver, compared to chemotherapy alone.
A Phase 3 Randomized 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis
Brief Summary: The primary objectives of the study by study part are: Part A: To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures, and to inform/confirm the final sample size …
UPCC 43419: Prospective Study of Immune Biomarkers in Patients with Multiple Myeloma
The objective of this exploratory observational cohort study is to obtain blood samples - and in some cases, bone marrow aspirate samples - from patients with multiple myeloma for study in the laboratory.
Evaluation of Enhanced Gastrointestinal Cancer Screening in Lymphoma Survivors Treated with Prior Radiation Therapy
Lymphoma survivors who were treated with prior radiation therapy have been shown to have an increased risk of cancers of the gastrointestinal system. This increased cancer risk may be due to damage to cells in your gastrointestinal system that is caused at the time of radiation. This research is being …
IMAGING OF PRIMARY OR RECURRENT GYNECOLOGICAL CANCER WITH [18F]FLUORTHANATRACE ([18F]FTT) PET/CT
Women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 30 evaluable subjects who have been recommended to start systemic therapy as part of …
